Difference between revisions of "Kenneth Hillan"

Revision as of 01:00, 2 October 2023

Country

United States

Birth - Death

Occupation

Business, Medicine

Description

Former Chief Therapeutics Officer, 23andMe (consumer genetics and research company) from 2019 to 2023. President of Research & Development at Archaogen (2011-2018). Served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in China.

Further Reading/Research

• https://www.linkedin.com/in/kenneth-hillan-713b5526/
• https://www.sangamo.com/board-of-directors/kenneth-hillan/
• https://theorg.com/org/23andme/org-chart/kenneth-hillan-m-b-c-h-b

Share on Facebook

Tweet